"Getting the dose right": Facts, a blueprint, and encouragements

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 1, 2007, Pages 12-14

  Peck, C C ^a   Cross, J T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; DRUG SAFETY; GENETICS; GOVERNMENT REGULATION; HUMAN; LEADERSHIP; MEDICINE; PHARMACOGENETICS; PHYSICIAN; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; GOVERNMENT REGULATION; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; PRACTICE GUIDELINES; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34250658781     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100215     Document Type: Short Survey

References (20)

1. Cross, J., Lee, H., Westelinck, A., Nelson, J., Grudzinskas, C. & Peck, C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol. Drug Saf. 11, 439-446 (2002).
2. Heerdink, E., Urquhart, J. & Leufkens, H.G. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol. Drug Saf. 11, 447-453 (2002).
3. Peck, C.C. et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51, 465-473 (1992).
4. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).
5. Food and Drug Administration Modernization Act of 1997. Public Law. (1997).
6. Peck, C.C., Rubin, D.B. & Sheiner, L.B. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin. Pharmacol. Ther. 73, 481-490 (2003).
7. Government Accounting Office. New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts. Government Accounting Office Report GAO_07_49 (2006).
8. Stanski, D.R., Rowland, M. & Sheiner, L.B. Getting the dose right: Report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) Conference on Optimizing Drug Development, 2005. J. Pharmacokinet. Pharmacodyn. 32, 199-211 (2005).
9. European Centre of Pharmaceutical Medicine. The ECPM Course 〈http://www.ecpm.ch/ecpm/english/ecpmcourse.html〉.
10. American Course on Drug Development and Regulatory Sciences 〈http://acdrs.ucsf.edu〉.
11. Bhattaram, V.A. et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. [online] 7, E503-E512 (2005) (doi:10.1208/aapsj070351) 〈http://www.aapsj.org/view.asp?art=aapsj070351〉.
12. Bhattaram, V.A. et al. Impact of pharmacometric reviews on new drug approval and labeling decisions: a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81, 213-221 (2007).
13. Food and Drug Administration. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products 〈http://www.fda. gov/oc/initiatives/criticalpath/whitepaper.html〉 (2004).
14. International Conference on Harmonization. ICH-E4 Dose-Response Information to Support Drug Registration. Geneva, Switzerland (1994).
15. Food and Drug Administration. Continuous Marketing Applications: Pilot 2 - Scientific Feedback and Interactions during Development of Fast Track Products under PDUFA (FDA, Rockville, MD, 2003).
16. FDA Concept Paper: End-of-Phase-2A Meetings with Sponsors Regarding Exposure-Response of IND and NDA Products (Center for Drug Evaluation and Research, FDA, Rockville, MD, 2003).
17. Food and Drug Administration. Exposure-Response Relationships: Study Design, Data Analysis, and Regulatory Applications (FDA, Rockville, MD, 2003).
18. Food and Drug Administration. General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products (FDA, Rockville, MD, 1998).
19. Food and Drug Administration. Critical Path Opportunities Initiated in 2006 (FDA, Rockville, MD, 2007).
20. Shah, R.R. Drug development and use in the elderly: search for the right dose and dosing regimen. Br. J. Clin. Pharmacol. 58, 452-469 (2004).